Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Ultrasound Technology to Diagnose and Treat Cardiovascular Disease

Ultrasound analysis leads the charge in advancements in diagnosing and treating cardiovascular disease. Intel’s Yehudit Levi and DiA Imaging Analysis’ Hila Goldman-Aslan joined Michelle Dawn Mooney for insights on the AI and technology advancements in ultrasound that provide better diagnosis and treatment of cardiovascular disease. Hila Goldman-Aslan says that early detection is the go-to strategy…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Intel on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Ultrasound analysis leads the charge in advancements in diagnosing and treating cardiovascular disease. Intel’s Yehudit Levi and DiA Imaging Analysis’ Hila Goldman-Aslan joined Michelle Dawn Mooney for insights on the AI and technology advancements in ultrasound that provide better diagnosis and treatment of cardiovascular disease.

Hila Goldman-Aslan says that early detection is the go-to strategy to prevent a significant cardiac incident or death. “And ultrasound is the leading modality to identify those abnormalities in the heart, and it’s been increasingly used in all kinds of settings. You can see an ultrasound and cardiac ultrasound being used at the point of care in the emergency rooms and the ICU.”

A 2020 article from the American College of cardiology notes a rise in cardiovascular disease. With one-third of global deaths in 2019 attributed to cardiovascular disease, it is critical to find preventative solutions to reduce these alarming numbers. And this situation is where AI can play an essential role. “Artificial intelligence is all about data,” says Yehudit Levi. “The health segment is unique in the sense that a lot of medical records have been collected through the years. Artificial intelligence software enables processing these masses of data.” The insights gleaned from all this data and knowledge, once made accessible to the medical staff, help highlight abnormalities that might otherwise prove difficult to detect.

DiA Imaging Analysis powered through Intel technology strives to allow for more efficient cardiovascular results and better treatment. “We see physicians looking for more automated procedures and processes to help them make better decisions based on more objective information,” Goldman-Aslan says. Until recently, the review of ultrasound images relied solely on the operator, which creates a layer of subjectivity. With AI analysis, the process becomes more objective and provides better information for the cardiovascular team to make decisions. The increase in cardiac procedures and a shortage of staff analysts available make DiA Imaging ultrasound analysis solutions integral.

“Improving the diagnostic time is super important,” Levi stresses. “It allows more patients to be diagnosed.” Together, DiA and Intel make these ultrasound capabilities scalable for healthcare.

Learn more about Health and Life Sciences by connecting with Yehudit Levi and Hila Goldman-Aslan on LinkedIn or visit: 

 Subscribe to this channel on Apple Podcasts, Spotify, and Google Podcasts to hear more from the Intel Internet of Things Group.

Intel

Part of this channel

Intel

Silicon and AI platforms powering enterprise and edge compute.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Microsoft’s 60% Dragon Copilot discount forces a new way to measure digital health ROI

Microsoft’s 60% Dragon Copilot discount forces a new way to measure digital health ROI

Microsoft has introduced a 60% discount for its Dragon Copilot, prompting a reevaluation of how digital health ROI is measured. The initiative targets rural hospitals, while European efforts like EDiHTA highlight the need for a consistent method to price technology evidence. This shift reflects a broader trend in healthcare towards data-driven decision-making and cost assessment.

  • 01Microsoft offers a 60% discount for Dragon Copilot aimed at rural hospitals.
  • 02There's a growing need for a standardized approach to pricing technology evidence in healthcare.
  • 03The European EDiHTA initiative exemplifies the trend of data-driven evaluation in digital health.

Aug 30, 2026

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512